Munich

• Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel … Ended recruitment
  2024-515783-31-00 5 2018-08-24 Newly Diagnosed Multiple Myeloma
• First-in-human study of AT132 in X-Linked Myotubular Myopathy (XLMTM) Patients Ended recruitment
  2024-512637-32-00 10 2018-08-21 X-linked Myotubular Myopathy (XLMTM)
• Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos … Ended recruitment
  2023-505341-23-00 5 2018-07-27 Non-muscle invasive bladder cancer
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended recruitment
  2023-509856-32-00 5 2018-07-15 acute lymphoblastic leukemia in children and adolescents
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended recruitment
  2024-510913-13-00 10 2018-05-18 Previously Untreated Metastatic or Unresectable Melanoma
• A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended recruitment
  2023-504802-12-00 7 2018-05-16 Lymphoma of B-cell origin
• MB-CART19.1 r/r CD19+ BCM Ended recruitment
  2024-513334-38-00 1 2018-05-15 Refractory/relapsed B-NHL
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended recruitment
  2024-513070-21-00 4 2018-02-15 Relapsed Acute Lymphoblastic Leukemia (ALL)
• This is a randomized, open-label, multi-center, global, Phase III study to assess the effectiveness and safety of two Immune Therapy drugs, … Ended recruitment
  2024-512212-21-00 5 2017-11-28 Advanced hepatocellular carcinoma (HCC)
• Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Ended recruitment
  2023-510444-21-00 5 2017-11-24 Neuroendocrine tumours of gastroenteric or pancreatic origin
• L19TNF plus doxorubicin in patients with STS Ended recruitment
  2024-512789-32-00 5 2017-10-09 Unresectable or metastatic soft tissue sarcoma
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination wi … Ended recruitment
  2023-509354-58-00 5 2017-07-14 Mantle Cell Lymphoma
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and … Ended recruitment
  2023-505509-18-00 5 2017-07-12 mature aggressive B-cell lymphoma and leukemia in children and adolesc
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended recruitment
  2023-509923-42-00 4 2017-07-06 HER2- positive breast cancer
• Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Expos … Ended recruitment
  2022-501763-40-00 5 2016-12-13 Pre-Exposure Prophylaxis of HIV-1 Infection
• CheckMate 274 Ended recruitment
  2022-500630-29-00 5 2016-05-06 Subjects with High Risk Invasive Urothelial Carcinoma
• PhII Trial of Pembrolizumab in Advanced Solid Tumors Ended recruitment
  2022-501253-37-00 4 2016-02-02 (A) Anal Squamous Cell Carcinoma, (B) Biliary Adenocarcinoma (gallblad
• EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) wit … Ended recruitment
  2024-513509-30-00 5 2016-01-11 Progressive or recurrent germ cell tumor (measurable or non-measurable
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun … Ended recruitment
  2023-505981-26-00 5 2015-11-20 Non−Small Cell Lung Cancer
• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Ended recruitment
  2023-509425-53-00 5 2015-11-09 Atopic Dermatitis
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEA … Ended recruitment
  2024-515619-23-00 4 2015-06-29 essential thrombocythemia

Showing 817–840 of 1,080 trials